RALEIGH, N.C. – TIME has named Sprout Pharmaceuticals among just 10 organizations globally shaping the future of health and life sciences.
This recognition follows a defining period of momentum for Sprout and its flagship treatment, Addyi. In December 2025, the U.S. Food and Drug Administration approved an expanded indication for Addyi to include all women under 65 with Hypoactive Sexual Desire Disorder (HSDD), regardless of menopausal status, unlocking a significantly broader patient population and accelerating commercial expansion.
Sprout has scaled Addyi into a nationally recognized brand with record-setting commercial growth, expanded prescriber adoption with 1000 new prescribers added each month and increased affordability and access.
Addyi is now the No. 1 prescribed treatment for frustrating low libido, women's most common sexual concern, and is backed by more than ten years of clinical and real-world patient data.
TIME evaluated companies based on impact, innovation, ambition, and success—selecting just 10 companies in health and life sciences as industry leaders. Sprout now stands alongside global powerhouses like Novo Nordisk and Genentech, a reflection of both its operating performance and its role in expanding the boundaries of modern healthcare.
"We built this company to challenge a system that told women to settle," said Cindy Eckert, Founder and CEO of Sprout Pharmaceuticals, "To now be recognized by TIME alongside the biggest forces in biotech is proof of what we've always believed - that when you refuse to accept the status quo, you don't just join the industry, you change it."
A special print issue featuring all TIME100 Companies Industry Leaders now available on newsstands. The full list is available now at: https://time.com/article/2026/04/27/time100-companies-health/
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
